vs
Apellis Pharmaceuticals, Inc.（APLS）与Skyward Specialty Insurance Group, Inc.（SKWD）财务数据对比。点击上方公司名可切换其他公司
Skyward Specialty Insurance Group, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.9倍（$385.6M vs $199.9M），Skyward Specialty Insurance Group, Inc.净利率更高（11.2% vs -29.5%，领先40.7%），Skyward Specialty Insurance Group, Inc.同比增速更快（26.7% vs -5.9%），Skyward Specialty Insurance Group, Inc.自由现金流更多（$402.6M vs $-14.3M），过去两年Skyward Specialty Insurance Group, Inc.的营收复合增速更高（20.6% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Skyward Specialty Insurance Group是一家专业财产和意外伤害保险提供商，推出商业车险、一般责任险、职业赔偿险、特种财产险等定制化保障方案，主要服务美国各地的中小企业及细分行业客户，专注承保服务不足群体的复杂高难度风险。
APLS vs SKWD — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $385.6M |
| 净利润 | $-59.0M | $43.2M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 14.2% |
| 净利率 | -29.5% | 11.2% |
| 营收同比 | -5.9% | 26.7% |
| 净利润同比 | -62.2% | 200.1% |
| 每股收益（稀释后） | $-0.40 | $1.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $385.6M | ||
| Q3 25 | $458.6M | $382.5M | ||
| Q2 25 | $178.5M | $319.9M | ||
| Q1 25 | $166.8M | $328.5M | ||
| Q4 24 | $212.5M | $304.4M | ||
| Q3 24 | $196.8M | $300.9M | ||
| Q2 24 | $199.7M | $279.9M | ||
| Q1 24 | $172.3M | $265.0M |
| Q4 25 | $-59.0M | $43.2M | ||
| Q3 25 | $215.7M | $45.9M | ||
| Q2 25 | $-42.2M | $38.8M | ||
| Q1 25 | $-92.2M | $42.1M | ||
| Q4 24 | $-36.4M | $14.4M | ||
| Q3 24 | $-57.4M | $36.7M | ||
| Q2 24 | $-37.7M | $31.0M | ||
| Q1 24 | $-66.4M | $36.8M |
| Q4 25 | -25.6% | 14.2% | ||
| Q3 25 | 48.7% | 15.8% | ||
| Q2 25 | -18.6% | 15.6% | ||
| Q1 25 | -50.0% | 15.7% | ||
| Q4 24 | -12.3% | 6.1% | ||
| Q3 24 | -24.0% | 15.6% | ||
| Q2 24 | -14.7% | 14.4% | ||
| Q1 24 | -36.0% | 17.7% |
| Q4 25 | -29.5% | 11.2% | ||
| Q3 25 | 47.0% | 12.0% | ||
| Q2 25 | -23.6% | 12.1% | ||
| Q1 25 | -55.3% | 12.8% | ||
| Q4 24 | -17.1% | 4.7% | ||
| Q3 24 | -29.2% | 12.2% | ||
| Q2 24 | -18.9% | 11.1% | ||
| Q1 24 | -38.5% | 13.9% |
| Q4 25 | $-0.40 | $1.03 | ||
| Q3 25 | $1.67 | $1.10 | ||
| Q2 25 | $-0.33 | $0.93 | ||
| Q1 25 | $-0.74 | $1.01 | ||
| Q4 24 | $-0.30 | $0.33 | ||
| Q3 24 | $-0.46 | $0.89 | ||
| Q2 24 | $-0.30 | $0.75 | ||
| Q1 24 | $-0.54 | $0.90 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $168.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $1.0B |
| 总资产 | $1.1B | $4.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $168.5M | ||
| Q3 25 | $479.2M | $160.1M | ||
| Q2 25 | $370.0M | $136.6M | ||
| Q1 25 | $358.4M | $112.9M | ||
| Q4 24 | $411.3M | $121.6M | ||
| Q3 24 | $396.9M | $105.6M | ||
| Q2 24 | $360.1M | $73.0M | ||
| Q1 24 | $325.9M | $85.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
| Q4 25 | $370.1M | $1.0B | ||
| Q3 25 | $401.2M | $961.4M | ||
| Q2 25 | $156.3M | $899.9M | ||
| Q1 25 | $164.2M | $850.7M | ||
| Q4 24 | $228.5M | $794.0M | ||
| Q3 24 | $237.1M | $797.5M | ||
| Q2 24 | $264.3M | $723.6M | ||
| Q1 24 | $266.7M | $692.3M |
| Q4 25 | $1.1B | $4.8B | ||
| Q3 25 | $1.1B | $4.6B | ||
| Q2 25 | $821.4M | $4.3B | ||
| Q1 25 | $807.3M | $4.0B | ||
| Q4 24 | $885.1M | $3.7B | ||
| Q3 24 | $901.9M | $3.6B | ||
| Q2 24 | $904.5M | $3.4B | ||
| Q1 24 | $831.9M | $3.2B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $408.1M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $402.6M |
| 自由现金流率自由现金流/营收 | -7.1% | 104.4% |
| 资本支出强度资本支出/营收 | 0.1% | 1.4% |
| 现金转化率经营现金流/净利润 | — | 9.44× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $755.2M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $408.1M | ||
| Q3 25 | $108.5M | $171.4M | ||
| Q2 25 | $4.4M | $88.2M | ||
| Q1 25 | $-53.4M | $96.8M | ||
| Q4 24 | $19.4M | $305.1M | ||
| Q3 24 | $34.1M | $168.0M | ||
| Q2 24 | $-8.3M | $21.0M | ||
| Q1 24 | $-133.0M | $94.3M |
| Q4 25 | $-14.3M | $402.6M | ||
| Q3 25 | $108.3M | $168.9M | ||
| Q2 25 | $4.4M | $87.1M | ||
| Q1 25 | $-53.4M | $96.6M | ||
| Q4 24 | $19.3M | $300.9M | ||
| Q3 24 | — | $167.6M | ||
| Q2 24 | $-8.4M | $18.4M | ||
| Q1 24 | $-133.3M | $94.0M |
| Q4 25 | -7.1% | 104.4% | ||
| Q3 25 | 23.6% | 44.2% | ||
| Q2 25 | 2.5% | 27.2% | ||
| Q1 25 | -32.0% | 29.4% | ||
| Q4 24 | 9.1% | 98.8% | ||
| Q3 24 | — | 55.7% | ||
| Q2 24 | -4.2% | 6.6% | ||
| Q1 24 | -77.3% | 35.5% |
| Q4 25 | 0.1% | 1.4% | ||
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | 0.0% | 0.3% | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 0.0% | 1.4% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | 0.0% | 0.9% | ||
| Q1 24 | 0.2% | 0.1% |
| Q4 25 | — | 9.44× | ||
| Q3 25 | 0.50× | 3.73× | ||
| Q2 25 | — | 2.27× | ||
| Q1 25 | — | 2.30× | ||
| Q4 24 | — | 21.18× | ||
| Q3 24 | — | 4.58× | ||
| Q2 24 | — | 0.68× | ||
| Q1 24 | — | 2.56× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
SKWD
暂无分部数据
